Impact of Glutathione-S-Transferases (GST) Polymorphisms and Hypermethylation of Relevant Genes on Risk of Prostate Cancer Biochemical Recurrence: A Meta-Analysis

Chen, Rui; Ren, Shancheng; Meng, Tong; Aguilar, Josephine; Sun, Yinghao

doi:10.1371/journal.pone.0074775

Cited by 21 publications

(16 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent meta-analysis based on 4 case-control studies and 7 cohort studies including 12 data sets and 3.037 PCa patients confirms the relation between PSA failure and Glutathione-S-transferases ( GSTM1 and GSTP1 ) polymorphisms and hypermethylation of GSTP1 and APC [27]. However, use of single gene hypermethylation for prediction of prognosis in PCa may produce unspecific results since it may also be present in other neoplasms and non-malignant tissues [9].…”

Section: Discussionmentioning

confidence: 99%

A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy

Angulo

López

Dorado³

et al. 2016

Urol Int

View full text Add to dashboard Cite

Purpose: Detection of DNA hypermethylation is emerging as a novel molecular biomarker for different malignancies. We intend to define whether a hypermethylation profile of patients with prostate cancer (PCa) predicts biochemical recurrence (BCR) after radical prostatectomy (RP). Material and Methods: Genome-wide methylation analysis was performed using the GoldenGate Methylation Cancer Panel-I (Illumina, Inc.) on 10 normal prostate tissues and 58 tumor samples from patients treated by RP followed for prostate-specific antigen (PSA) failure (>0.4 ng/ml) and disease progression. Patients were classified on the basis of D'Amico criteria according to clinical staging, PSA at diagnosis and Gleason score after pathologist review. Hypermethylation status of 1505 CpGs present in the promoter region of 807 genes was studied. Hierarchical clustering analysis was performed and relationships with outcome were investigated using log-rank analysis and Cox regression model. Results: We found 28 genes significantly hypermethylated in >20% of the tumors analyzed. Four clusters of patients were characterized by their DNA methylation profile, one at higher risk to develop BCR (p = 0.005). Multivariate analysis revealed patients in this cluster (HR 2.56), and high-risk patients (HR 4.34) according to D'Amico classification were independent predictors of BCR after prostatectomy. From the selected genes MT1A, ALOX12, GSTM2, APC, MYCL2 and RARB hypermethylation predicted BCR and GSTM2 (HR 3.78) and MYCL2 hypermethylation (HR 2.71) did so independently. Conclusion: Epigenetic silencing of GSTM2 and MYCL2 comprise novel molecular markers to predict BCR after surgery for medium- and high-risk localized PCa undergoing surgical treatment and hypermethylation of these genes could be incorporated to the clinical and pathological factors defining the patient at higher risk of PSA failure after prostatectomy. The limitation of the study is that no independent validation cohort is analysed.

show abstract

Section: Discussionmentioning

confidence: 99%

A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy

Angulo

López

Dorado³

et al. 2016

Urol Int

View full text Add to dashboard Cite

show abstract

“…Pathologic stage, Gleason score, and surgical margin status are independent predictors of biochemical recurrence and are used in nomograms to predict outcome (10). A recent meta-analysis has shown that GSTP1 hypermethylation may also be a potential predictive biomarker (11).…”

Section: Introductionmentioning

confidence: 99%

Effect of Sulforaphane in Men with Biochemical Recurrence after Radical Prostatectomy

Cipolla¹,

Mandron²,

Lefort³

et al. 2015

Cancer Prevention Research

111

106

View full text Add to dashboard Cite

Increases in serum levels of prostate-specific antigen (PSA) occur commonly in prostate cancer after radical prostatectomy and are designated "biochemical recurrence." Because the phytochemical sulforaphane has been studied extensively as an anticancer agent, we performed a double-blinded, randomized, placebo-controlled multicenter trial with sulforaphane in 78 patients (mean age, 69 AE 6 years) with increasing PSA levels after radical prostatectomy. Treatment comprised daily oral administration of 60 mg of a stabilized free sulforaphane for 6 months (M0-M6) followed by 2 months without treatment (M6-M8). The study was designed to detect a 0.012 log (ng/mL)/month decrease in the log PSA slope in the sulforaphane group from M0 to M6. The primary endpoint was not reached. For secondary endpoints, median log PSA slopes were consistently lower in sulforaphanetreated men. Mean changes in PSA levels between M6 and M0 were significantly lower in the sulforaphane group (þ0.099 AE 0.341 ng/mL) than in placebo (þ0.620 AE 1.417 ng/mL; P ¼ 0.0433). PSA doubling time was 86% longer in the sulforaphane than in the placebo group (28.9 and 15.5 months, respectively). PSA increases >20% at M6 were significantly greater in the placebo group (71.8%) than in the sulforaphane group (44.4%); P ¼ 0.0163. Compliance and tolerance were very good. Sulforaphane effects were prominent after 3 months of intervention (M3-M6). After treatment, PSA slopes from M6 to M8 remained the same in the 2 arms. Daily administration of free sulforaphane shows promise in managing biochemical recurrences in prostate cancer after radical prostatectomy. Cancer Prev Res; 8(8); 712-9. Ó2015 AACR.

show abstract

“…Enhanced reduce representation bisulfite sequencing (ERRBS) can detect genome-wide DNA methylation at single-base resolution including CGI shores and allele-specific methylation (ASM) at various regions (Lin et al 2013). Based on the ChIP-Seq, Chen et al, 2013 showed that ERG restores an androgen receptor (AR) transcriptome in PTEN-deleted PCa. In addition, methylated DNA immunoprecipitation sequencing (MeDIP-Seq) method involves isolation of methylated fragments of the genome by using an antibody (Thu et al 2009).…”

Section: Identifying Pca Mutations Using Next Generation Sequencing Mmentioning

confidence: 99%

“…CpG island hypermethylation of glutathione-S-transferase P (GSTP1) promoter DNA, resulting in the loss of GSTP1 expression (Lin et al 2001). A number of methylation profiles have been developed and are being evaluated as potential markers for early diagnosis and risk assessment (Chen et al 2013). In the recent-past, iCLIP-Seq methods to infer RNA-Protein interactions at a higher resolution is made available (Huppertz et al 2014).…”

Section: Identifying Pca Mutations Using Next Generation Sequencing Mmentioning

confidence: 99%

Revisiting Prostate Cancer in India: A Genomic View<strong> </strong><strong> </strong>

Perera¹,

Gupta²,

Shukla³

et al. 2019

Preprint

View full text Add to dashboard Cite

In the recent past, there has been a rise in Prostate Cancer (PCa) in Asia, particularly India.  Although systematic reviews on PCa have dealt on the genetics, genomics and the environmental influence in causal of PCa, no predictive analytics in comparing the PCa from Caucasian, American to Asian population was attempted. In this review article, we have attempted to elaborate this aspect of PCa and deliberated on challenges related to next generation sequencing methods of PCa’s manifestation when compared to the west.

show abstract

Impact of Glutathione-S-Transferases (GST) Polymorphisms and Hypermethylation of Relevant Genes on Risk of Prostate Cancer Biochemical Recurrence: A Meta-Analysis

Cited by 21 publications

References 34 publications

A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy

A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy

Effect of Sulforaphane in Men with Biochemical Recurrence after Radical Prostatectomy

Revisiting Prostate Cancer in India: A Genomic View<strong> </strong><strong> </strong>

Contact Info

Product

Resources

About